UCHL5 and renal cell adenocarcinoma: In contrast to BAP1, which inhibits RCC by upregulation of STING activity and activation of interferon, UCHL5 promotes RCC by regulating immune infiltration and antigen presentation of B cells, and its increased level in RCC blood samples suggest its potential as a prognostic marker.